Insider trade

Immunovant (IMVT): Director sold ~$108K

Atul Pande, Director at Immunovant, sold ~$108K of Immunovant shares.

~$108K
Approx. value · 3,000 sh @ $36.00
117K
Holds after · shares reported
Traded
Nov 11, 2026
Filed
Nov 12, 2026

What stands out in this filing

  • The sale was 2.5% of the shares this insider held before it; the filing reports 116,731 shares afterwards.
  • 3,000 shares at an average of $36.00 each, as reported on the form.
  • Footnote references a pre-arranged trading plan (Rule 10b5-1).

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 23, 2026InsiderOfficer sold ~$103K of IMVT shares in the open market
  2. Oct 2, 2026InsiderCEO sold ~$120K of IMVT shares in the open market
  3. Oct 7, 2026Insider · 3 peopleInsiders: 4 sales (~$237K)
  4. Oct 21, 2026InsiderOfficer sold ~$75K of IMVT shares in the open market
  5. Oct 28, 2026InsiderCFO sold ~$188K of IMVT shares in the open market
  6. Nov 9, 2026Company filing · Form 8-K · ResultsReported its results
  7. Nov 11, 2026 · this disclosureInsiderDirector sold ~$108K of IMVT shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Immunovant

For Immunovant, OQRO holds 10 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IMVT page.

Other recent filings by Atul Pande, Director

The full history of Atul Pande, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Immunovant (IMVT) insider traded, and how much?

Atul Pande, Director at Immunovant, sold ~$108K of Immunovant shares. 3,000 shares at $36.00.

When did it happen, and when was it made public?

Traded: Nov 11, 2026. Filed: Nov 12, 2026. That is 1 day between the two dates.

What stands out in this filing?

The sale was 2.5% of the shares this insider held before it; the filing reports 116,731 shares afterwards. 3,000 shares at an average of $36.00 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Immunovant recently?

For Immunovant, OQRO holds 10 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the IMVT page.

Does this mean IMVT stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Immunovant

Everything OQRO holds on this company is on its IMVT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data